Senior Scientist I, Clinical Biomarker Development

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

Requirements

• Design and execute clinical biomarker strategies to support early response monitoring, patient stratification, and understanding resistance mechanisms.
• Support biomarker implementation for early- and late-stage oncology clinical trials.
• Oversee biomarker assay development, qualification, and sample analysis in collaboration with internal teams and external CROs.
• Analyze and interpret biomarker data in the context of clinical outcomes and present results to cross-functional teams.
• Contribute to clinical protocols, study reports, and regulatory documents (e.g., INDs, IBs, CSRs).
• Translate preclinical findings into clinically actionable biomarker hypotheses.

Benefits

• Competitive cash compensation
• Robust equity awards
• Strong benefits
• Significant learning and development opportunities